Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker. The pharma giant has a long history of successfully developing and marketing new drugs.
When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business.
Three drugmakers promise retirees steady paychecks, yet one faces a looming Eliquis cliff and two pay in foreign currencies that can shrink the check. Which dividend is safest when earnings look shaky but cash tells a different story?
Vanguard quietly runs an actively managed value fund that hunts for bargains across every company size, and it just beat its famous index sibling over the past year. Before you switch, check what it asks of you in return.
MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday released preliminary Phase 3 data showing that short- and long-term KarXT treatment reduced symptoms in patients experiencing psychosis associated with Alzheimer's disease.